

Stacey Adam

Discloser Identifier: 1088380

Disclosure Purpose: 22-09421

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Inhaled Fluticasone for Outpatient Treatment of Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

David Boulware

Discloser Identifier: 360309

Disclosure Purpose: 22-09421

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Inhaled Fluticasone for Outpatient Treatment of Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 971690

Disclosure Purpose: 22-09421

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Arrowhead Pharmaceuticals	Consultant	Self
Category: Consultant Description: Additional Information:		
AstraZeneca	Grant / Contract	Self
Recipient Name: University of Kansas School of Medicine Grant / Contract Description: Additional Information: Recipient Type: Institution Grant / Contract Purpose: Research 		
AstraZeneca	Other	Self
Category: Other Description: Speaking engagements on disease state Additional Information: Speaking engagements on disease state, University Grant funding		
GALATHERAPEUTICS	Grant / Contract	Self
Recipient Name: University of Kansas School of Medicine Grant / Contract Description: Additional Information: Recipient Type: Institution Grant / Contract Purpose: Research 		
Genentech	Other	Self
Category: Other Description: Speaking engagements on disease state, Consulting fees Additional Information:		
MedLearningGroup	Other	Self
Category: Other Description: Speaker, unbranded programs Additional Information:		
Novartis	Grant / Contract	Self
Recipient Name: University of Kansas School of Medicine Grant / Contract Description: University grant funding Additional Information: University grant funding Recipient Type: Institution Grant / Contract Purpose: Research 		
OM Pharma	Consultant	Self
Category: Consultant Description: Additional Information:		

Entity	Type	Interest Held By
Pioneering Medicines	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Pulmatrix	Grant / Contract	Self
<i>Recipient Name:</i> University of Kansas School of Medicine <i>Grant / Contract Description:</i> University grant funding <i>Additional Information:</i> University grant funding <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Regeneron Pharmaceuticals	Other	Self
<i>Category:</i> Other <i>Description:</i> Speaking engagements on disease state <i>Additional Information:</i>		
Regeneron Pharmaceuticals, Inc.	Grant / Contract	Self
<i>Recipient Name:</i> University of Kansas School of Medicine <i>Grant / Contract Description:</i> University Grand Funding <i>Additional Information:</i> <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
SANOFI US SERVICES INC.	Grant / Contract	Self
<i>Recipient Name:</i> University of Kansas School of Medicine <i>Grant / Contract Description:</i> <i>Additional Information:</i> <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
SANOFI US SERVICES INC.	Other	Self
<i>Category:</i> Other <i>Description:</i> Speaking engagements on disease state, consulting <i>Additional Information:</i>		
Teva Pharmaceutical Industries	Other	Self
<i>Category:</i> Other <i>Description:</i> Speaking engagements on disease state <i>Additional Information:</i>		
Theravance Biopharma Inc.	Grant / Contract	Self
<i>Recipient Name:</i> University of Kansas School of Medicine <i>Grant / Contract Description:</i> <i>Additional Information:</i> <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Theravance Biopharma Inc.	Other	Self
<i>Category:</i> Other <i>Description:</i> Speaker for unbranded programs <i>Additional Information:</i>		

Intellectual Property

Type	Is Licensed	Interest Held By
Copyright - Royalties from books, under \$500USD/annum	-	Self

Type	Is Licensed	Interest Held By
<i>Description:</i> Royalties from books, under \$500USD/annum <i>Filing Jurisdiction:</i> USA <i>Licensees:</i> <i>Additional Information:</i> Book chapters		<i>Copyright Number:</i> <i>Copyright Holder:</i> Discloser

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Inhaled Fluticasone for Outpatient Treatment of Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Sean Collins

Discloser Identifier: 972237

Disclosure Purpose: 22-09421

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Enanta	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
National Center for Advancing Translational Sciences	Grant / Contract	Self
<i>Recipient Name:</i> Vanderbilt University Medical Center <i>Grant / Contract Description:</i> <i>Additional Information:</i> <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
National Heart, Lung, and Blood Institute	Grant / Contract	Self
<i>Recipient Name:</i> Vanderbilt University Medical Center <i>Grant / Contract Description:</i> <i>Additional Information:</i> <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
vir biotechnology	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Allison DeLong

Discloser Identifier: 1088382

Disclosure Purpose: 22-09421

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Sarah Dunsmore

Discloser Identifier: 1088378

Disclosure Purpose: 22-09421

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Gary Felker

Discloser Identifier: 441772

Disclosure Purpose: 22-09421

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Nina Gentile

Discloser Identifier: 1088376

Disclosure Purpose: 22-09421

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

"Inhaled Fluticasone for Outpatient Treatment of Covid-19"

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Adit Ginde

Discloser Identifier: 972239

Disclosure Purpose: 22-09421

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AbbVie	Grant / Contract	Self
<i>Recipient Name:</i> Adit Ginde <i>Grant / Contract Description:</i> Investigator initiated research grant for COVID-19 outpatient trial, outside the submitted work <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Faron Pharmaceuticals	Grant / Contract	Self
<i>Recipient Name:</i> Adit Ginde <i>Grant / Contract Description:</i> Investigator initiated research grant for COVID-19 inpatient trial, outside the submitted work <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Inhaled Fluticasone for Outpatient Treatment of Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

George Hanna

Discloser Identifier: 1088383

Disclosure Purpose: 22-09421

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AbPro	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Infectious Diseases Scientific Advisory Board <i>Additional Information:</i>		
Bristol-Myers Squibb	Stock	Self
<i>Additional Information:</i>		
Merck	Stock	Self
<i>Additional Information:</i>		
Tunnell Government Services	Employment	Self
<i>Title:</i> Clinical Subject Matter Expert Supporting BARDA <i>Position Description:</i> Subject matter expert in clinical development supporting BARDA <i>Additional Information:</i> Supporting US Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA)		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 465148

Disclosure Purpose: 22-09421

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
American Regent	Grant / Contract	Self
<i>Recipient Name:</i> Duke University <i>Grant / Contract Description:</i> Clinical Trials <i>Additional Information:</i> HEART-FID		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
American Regent	Grant / Contract	Self
<i>Recipient Name:</i> Duke University <i>Grant / Contract Description:</i> Clinical trial grant-HEARTFID <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Amgen	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Heart failure consultant <i>Additional Information:</i>		
AstraZeneca	Grant / Contract	Self
<i>Recipient Name:</i> Duke University <i>Grant / Contract Description:</i> Clinical Trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
AstraZeneca	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Heart failure; diabetes <i>Additional Information:</i>		
Bayer	Grant / Contract	Self
<i>Recipient Name:</i> Duke Clinical Research Institute <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Bayer	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> heart failure <i>Additional Information:</i>		
Boehringer Ingelheim	Grant / Contract	Self
<i>Recipient Name:</i> Duke University <i>Grant / Contract Description:</i> clinical trial <i>Additional Information:</i> Research Grant to DCRI for EMPCAT-MI		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Entity	Type	Interest Held By
Boehringer Ingelheim	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> consultant <i>Additional Information:</i>		
Boston Scientific Corporation	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> heart failure <i>Additional Information:</i>		
CSL Behring	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> atherosclerosis <i>Additional Information:</i>		
Cytokinetics	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> heart failure <i>Additional Information:</i>		
Duke Clinical Research Institute	Employment	Self
<i>Title:</i> Executive Director; Vice Dean of Duke School of Medicine <i>Additional Information:</i>		<i>Position Description:</i> Oversee the DCRI and part of the Duke School of Medicine Leadership
Eidos	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Description:</i> amyloid trial <i>Additional Information:</i>		
Eli Lilly and Company	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Heart failure/diabetes <i>Additional Information:</i>		
FibroGen	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> FDA mock panel <i>Additional Information:</i>		
Intercept Pharmaceuticals, Inc.	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Description:</i> NASH <i>Additional Information:</i>		
Merck	Grant / Contract	Self
<i>Recipient Name:</i> Duke University <i>Grant / Contract Description:</i> VICTORIA trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Merck	Consultant	Self

Entity	Type	Interest Held By
<i>Category:</i> Consultant <i>Description:</i> heart failure <i>Additional Information:</i>		
Novartis	Grant / Contract	Self
<i>Recipient Name:</i> Duke University <i>Grant / Contract Description:</i> CONNECT-HF; PARAGLIDe <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Novartis	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> HF and atherosclerosis <i>Additional Information:</i>		
Novo Nordisk	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Consultant on pragmatic clinical trials <i>Additional Information:</i>		
Relypsa, Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> hyperkalemia <i>Additional Information:</i>		
Verily	Grant / Contract	Self
<i>Recipient Name:</i> Duke University <i>Grant / Contract Description:</i> Project Baseline Research Grant <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

dushyantha jayaweera

Discloser Identifier: 482763

Disclosure Purpose: 22-09421

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Theratechnologies Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> scientific committee <i>Additional Information:</i> hourly rate		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial"

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Christopher Lindsell

Discloser Identifier: 877166

Disclosure Purpose: 22-09421

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Bioscape Digital	Stock Option	Self
Additional Information: Stock options valued at \$5,000 at the time of granting, with a ten year option period. The expiration is in 2023		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Matthew McCarthy

Discloser Identifier: 1088375

Disclosure Purpose: 22-09421

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Inhaled Fluticasone for Outpatient Treatment of Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Kathleen McTigue

Discloser Identifier: 505553

Disclosure Purpose: 22-09421

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
American Heart Association	Grant / Contract	Self
<i>Recipient Name:</i> <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> <i>Grant / Contract Purpose:</i>
Janssen Pharmaceuticals	Grant / Contract	Self
<i>Recipient Name:</i> <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> <i>Grant / Contract Purpose:</i>
Pfizer	Grant / Contract	Self
<i>Recipient Name:</i> <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> <i>Grant / Contract Purpose:</i>

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Inhaled Fluticasone for Outpatient Treatment of Covid-19

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 603891

Disclosure Purpose: 22-09421

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AbbVie	Grant / Contract	Self
<i>Recipient Name:</i> Susanna Naggie <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i>
Bristol Myers Squibb Company	End Point Review Committee	Self
<i>Category:</i> End Point Review Committee <i>Description:</i> <i>Additional Information:</i>		
Gilead Sciences	Grant / Contract	Self
<i>Recipient Name:</i> Susanna Naggie <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i>
NIH Office of the Director	Grant / Contract	Self
<i>Recipient Name:</i> Susanna Naggie <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i>
Pardes	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		
Personal Health Insights	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Description:</i> <i>Additional Information:</i>		
Silverback	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> No financial payments <i>Additional Information:</i>		
Vir Bio	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		

Entity	Type	Interest Held By
Vir Bio	Stock	Self
<i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Inhaled Fluticasone for Outpatient Treatment of Covid-19

3. **Are you the corresponding author?**

Yes.

- a. **Please list the other authors' names here.**

David R. Boulware, MD, MPH,¹ Christopher J. Lindsell, PhD,² Thomas G. Stewart, PhD,^{2*} Adrian F. Hernandez, MD, MHS,³ Sean Collins, MD, MSci,² Matthew William McCarthy, MD,⁴ Dushyantha Jayaweera, MD,⁵ Nina Gentile, MD,⁶ Mario Castro, MD, MPH,⁷ Mark Sulkowski, MD,⁸ Kathleen McTigue, MD, MPH, MS,⁹ G. Michael Felker, MD, MHS,³ Adit A. Ginde, MD, MPH,¹⁰ Sarah E. Dunsmore, PhD,¹¹ Stacey J. Adam, PhD,¹² Allison DeLong, BS,³ George Hanna, MD,¹³ April Remaly, BA,³ Florence Thicklin,¹⁴ Rhonda Wilder, MS,³ Sybil Wilson, RN,³ Elizabeth Shenkman, PhD,¹⁵ Susanna Naggie, MD, MHS³

Certification

I certify that the information provided in this disclosure is complete and accurate.

April Remaly

Discloser Identifier: 1088386

Disclosure Purpose: 22-09421

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

The Effects of Fluticasone on patients with mild to moderate COVID.

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Elizabeth Shenkman

Discloser Identifier: 1010394

Disclosure Purpose: 22-09421

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Inhaled Fluticasone for Outpatient Treatment of Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Thomas Stewart

Discloser Identifier: 1088373

Disclosure Purpose: 22-09421

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Eli Lilly and Company	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Description:</i> Independent data monitoring committee member for clinical trials <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Inhaled Fluticasone for Outpatient Treatment of Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 456956

Disclosure Purpose: 22-09421

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AbbVie	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Scientific advisory board related to hepatitis C and other viruses <i>Additional Information:</i>		
Aligos	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Scientific advisor related to hepatitis B <i>Additional Information:</i>		
Antios	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Scientific advisor related to hepatitis B <i>Additional Information:</i>		
Assembly Bioscience	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Scientific advisor related to hepatitis B <i>Additional Information:</i>		
Atea Pharmaceutical	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Scientific advisor related to COVID-19 and hepatitis C <i>Additional Information:</i>		
Gilead Sciences (aka Gilead Foundation)	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Scientific advisor related to hepatitis C and other viruses <i>Additional Information:</i>		
GlaxoSmithKline	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Scientific advisor related to hepatitis B <i>Additional Information:</i>		
Precision Biosciences	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Scientific advisor related to hepatitis B <i>Additional Information:</i>		

Entity	Type	Interest Held By
ViiV Healthcare	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Scientific advisor related to fatty liver disease/HIV <i>Additional Information:</i>		
WILEY	Other	Self
<i>Category:</i> Other <i>Description:</i> Editorial Board, Journal of Viral Hepatitis <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Inhaled Fluticasone for Outpatient Treatment of Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Florence Thicklin

Discloser Identifier: 1088387

Disclosure Purpose: 22-09421

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Inhaled Fluticasone for Outpatient Treatment of Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Rhonda Wilder

Discloser Identifier: 817309

Disclosure Purpose: 22-09421

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Sybil Wilson

Discloser Identifier: 1088388

Disclosure Purpose: 22-09421

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.